NASDAQ$BDTX
Black Diamond Therapeutics I · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided a corporate update.
Black Diamond Therapeutics reported its third quarter 2024 financial results, highlighting encouraging initial Phase 2 data of BDTX-1535 in recurrent EGFRm NSCLC and a corporate restructuring to prioritize BDTX-1535 development and extend cash runway into Q2 2026.
- Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC in September 2024.
- Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress.
- Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025.
- Cash, cash equivalents, and investments of $112.7 million as of September 30, 2024; expected to be sufficient to fund operations into Q2 of 2026.
Headline financials
Revenue & EPS history
Black Diamond Therapeutics · Revenue · Quarterly
$989K
Forward guidance
Black Diamond expects to disclose initial Phase 2 data in first-line EGFRm NSCLC patients with non-classical mutations as well as updated Phase 2 results in the recurrent EGFRm NSCLC setting in Q1 2025. The company believes its cash, cash equivalents and investments will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second quarter of 2026.
Tailwinds
- Potential for BDTX-1535 to address unmet medical need for newly diagnosed NSCLC patients with non-classical EGFR mutations.
- Continued development and advancement of BDTX-1535, including ongoing clinical trials.
- Expected timing for regulatory feedback and the disclosure of potential registrational pathways for BDTX-1535 in NSCLC.
- Potential future development plans for BDTX-1535 in NSCLC and GBM.
- Expected cost savings from the corporate restructuring plan.
Headwinds
- Uncertainties regarding the clinical development and regulatory approval of BDTX-1535.
- Risks associated with potential delays or setbacks in clinical trials.
- Uncertainties regarding the successful execution of the corporate restructuring plan.
- Dependence on partnerships for BDTX-4933.
- Potential impact of risks and uncertainties set forth in the company's filings with the SEC.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.4%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-1.6%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+15.6%
Q4 2019
Best reaction
-19.6%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | +0.0% | -30.5% | |
| Q4 2025 | +2.4% | -3.7% | +33.3% | |
| Q3 2025 | -8.1% | -1.5% | -31.4% | |
| Q1 2025 | +2.1% | +5.2% | +19.7% | |
| Q4 2024 | -1.8% | +4.1% | -15.8% | |
| Q3 2024 | +10.0% | +10.0% | -21.4% | |
| Q2 2024 | -14.0% | -12.5% | +5.3% | |
| Q1 2024 | -12.0% | -17.3% | -25.2% | |
| Q4 2023 | +4.8% | +19.7% | +39.3% | |
| Q3 2023 | -4.2% | -6.3% | +24.7% | |
| Q2 2023 | -3.5% | -9.7% | +2.3% | |
| Q1 2023 | -2.1% | -1.6% | +11.5% | |
| Q4 2022 | -19.6% | +3.6% | -3.0% | |
| Q3 2022 | -2.7% | +13.6% | -28.1% | |
| Q2 2022 | +4.5% | +4.3% | -21.8% | |
| Q1 2022 | -9.4% | -8.4% | +5.4% | |
| Q4 2021 | +8.2% | +7.8% | +16.4% | |
| Q3 2021 | +2.0% | -4.0% | -22.8% | |
| Q2 2021 | -1.8% | -1.3% | +4.3% | |
| Q1 2021 | -4.0% | +9.0% | -50.3% | |
| Q4 2020 | +2.1% | +0.7% | +19.0% | |
| Q3 2020 | +9.2% | +3.2% | +8.1% | |
| Q2 2020 | -9.2% | -11.4% | -11.6% | |
| Q1 2020 | -1.1% | -5.4% | -19.5% | |
| Q4 2019 | +15.6% | +0.4% | +51.7% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro